MYC and medulloblastoma: Here, we report that Axitinib displays anti‐proliferative, anti‐clonogenic and pro‐apoptotic activity in cell lines modelling the most aggressive c‐myc‐amplified Non‐WNT/Non‐SHH and SHH‐TP53‐mutated medulloblastoma variants associated with a very poor prognosis 24, 25, 26, 27, 28, 29, 30.